WO1995002357A1 - Noninvasive glucose monitor - Google Patents

Noninvasive glucose monitor Download PDF

Info

Publication number
WO1995002357A1
WO1995002357A1 PCT/US1994/006684 US9406684W WO9502357A1 WO 1995002357 A1 WO1995002357 A1 WO 1995002357A1 US 9406684 W US9406684 W US 9406684W WO 9502357 A1 WO9502357 A1 WO 9502357A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucose
patient
skin
collection medium
reservoir
Prior art date
Application number
PCT/US1994/006684
Other languages
French (fr)
Inventor
Nooshin T. Azimi
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Priority to JP7504544A priority Critical patent/JPH09503924A/en
Priority to EP94920190A priority patent/EP0708615A4/en
Priority to AU71073/94A priority patent/AU7107394A/en
Publication of WO1995002357A1 publication Critical patent/WO1995002357A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement

Definitions

  • This invention relates generally to methods and apparatus for glucose collection and concentration measurement.
  • the invention is directed to a method and apparatus for monitoring blood glucose levels noninvasively through a patient's skin.
  • U.S. Patent No. 5,036,861 describes a glucose monitor that collects the patient's sweat through a skin patch attached to the patient's wrist. Iontophoresis is used to transdermally introduce a gel into the patient's skin. The gel contains a cholinergic agent for stimulating the secretion mechanism of the eccrine sweat gland and agents that minimize or prevent loss of glucose from the sweat as it travels from the sweat gland to the skin patch. As in the '532 patent, the device described in the '861 patent measures the glucose level in the collected sweat using electrodes.
  • U.S. Patent No. 5,139,023 describes yet another "noninvasive" apparatus and method for monitoring blood glucose.
  • the monitor includes a glucose receiving medium such as water enclosed in a housing that holds the receiving medium against the patient's epithelial membrane.
  • the glucose receiving medium includes a permeation enhancing chemical such as a natural bile salt that enhances glucose permeability from interstitial fluid across the epithelial membrane into the monitor.
  • published European Patent Application EP 0 304 304 discloses a transdermal glucose detection system in which the detector contains a porous carrier saturated with detector chemicals.
  • the detector adhesively attaches to the patient's skin.
  • a membrane serves as a barrier to prevent migration of the detector chemicals out of the detector while permitting glucose to migrate into the detector. Interaction between glucose and the detector chemicals causes a perceivable color change over a six to twelve hour period.
  • the device only detects the presence of glucose; it does not measure the actual amount of glucose in the detector.
  • This invention provides a truly noninvasive glucose monitoring apparatus and method that does not rely upon heat, electricity or chemicals to collect glucose from interstitial fluid across the patient's skin. Moreover, the method and apparatus of this invention monitor blood glucose in real time, that is to say, in a time period short enough to enable a diabetic to take appropriate action to correct blood glucose levels.
  • a collection device comprising a reservoir containing a glucose collection medium such as water is placed against the stratum corneum of the patient's skin for a predetermined period of time. At least a portion of the glucose collection medium is removed from the reservoir at the end of the predetermined time and analyzed for glucose concentration.
  • a glucose collection medium such as water
  • Figure 1 is a side cross-sectional view of a glucose collection device according to the preferred embodiment of this invention.
  • Figure 2 is a bottom elevational view of the preferred glucose collection device.
  • Figure 3 is a cross-sectional view of a sensor for use with a glucose analysis method for use with this invention.
  • FIG. 4 is a schematic representation of a glucose monitoring system according to this invention.
  • This invention presents a simple and noninvasive method for monitoring blood glucose levels. It is well-known that glucose can be found in a patient's interstitial fluid and in a patient's sweat. Heretofore, however, it had been thought that glucose could not cross the patient's skin in a detectable amount in real time without the use of a permeability enhancer. See, e.g., U.S. Patent No. 5,139,023 at col. 7, line 3. It had also been thought that even when sweat or interstitial fluid is actively extracted from the patient, active pharmacological agents are needed to preserve the presence of glucose in the extracted sample. See, e.g., U.S. Patent No. 5,036,861, col. 3, lines 1-10.
  • This invention is a method and apparatus for detecting blood glucose in a truly noninvasive manner without actively extracting interstitial fluid from the patient and without the use of sweat inducers, glucose preservers or permeability enhancers.
  • glucose is collected through the stratum corneum of the patient's skin by a reservoir containing a glucose collection medium. After the passage of a predetermined time period, the glucose collection medium is analyzed to measure the quantity of glucose present.
  • a preferred collection device for practicing this invention is shown in Figures 1 and 2.
  • the device 10 comprises a reservoir 12 bordered by a cover 14, adhesive layer 16, and the stratum corneum of the patient's skin 18.
  • the device is formed by attaching the plastic cover 14 to a double-sided adhesive 16 in which an oval or other-shaped hole has been formed.
  • cover 14 is formed from cellophane plastic and adhesive layer 16 is Avery double-sided adhesive, part no. MED 3044.
  • the preferred glucose collection medium is distilled deionized water.
  • the distilled deionized water is injected into reservoir 12 through a hypodermic needle and syringe 20.
  • glucose will migrate from the patient's interstitial fluid through the skin 18 and into the water within reservoir 12. After the water has rested against the patient's skin for a predetermined period of time, the water is withdrawn for analysis.
  • This glucose collection device and method can collect glucose from the patient without the use of chemicals or mechanical extraction.
  • hydrogel may be used as a collection medium. Suitable hydrogels are described in U.S. Patent No. 5,139,023.
  • Water (or other collection medium) from the reservoir may be extracted at periodic intervals (preferably in the range of 5 to 10 minutes) and analyzed to determine its glucose content.
  • a preferred glucose analysis method is described by LaCourse et al. in "Optimization of Waveforms for Pulsed Amperometric Detection of Carbohydrates Based on Pulsed Voltammetry, " 65 Analytical Chemistry 50-55 (1 January 1993) , although other analysis methods may be used.
  • the preferred pulse amperometric voltammetry (PAD) analysis method combines high performance liquid chromatography with electrochemical detection using bi-directional voltage waveforms. Specifically, water extracted from the reservoir is diffused onto a chromatography column. The column is washed with a high pressure solvent such as a NaOH solution.
  • a stepped voltage waveform is applied across two electrodes in the solution, one of which is a gold rotating disk electrode.
  • the voltage waveform has three parts: a detection potential in the range of -200 to +400 mV for greater than 40 ms detection period, an oxidation potential in the range of 300 to 800 mV for greater than approximately 60 ms, and a reduction potential in the range of -800 to +100 mV for greater than approximately 60 ms.
  • a plot of electrode current at the gold electrode versus applied voltage yields a curve with signature peaks at specific voltage values for certain solutes such as glucose. The peak amplitude or peak area are measures of the concentration of that solute.
  • An alternative glucose concentration analysis method is shown schematically in Figures 3 and 4.
  • the glucose measurement technique of this embodiment is similar to the enzymatic technique described in U.S. Patent No. 5,165,407 and does not require the glucose collection medium to be extracted from the collection device.
  • a glucose sensor 30 is shown in detail in Figure 3.
  • a sensor body 32 is received within a stainless steel hollow tubular needle 34.
  • the sensor body includes a Teflon-coated platinum-iridium wire 36
  • a glucose oxidase layer 40 is immobilized within the cavity 38, and comprises a cellulose acetate polymer layer attached to the surface of the Pt-Ir wire, with glucose oxidase crosslinked through glutaraldehyde onto the cellulose acetate to form an indicating electrode.
  • the procedure is described in more detail in U.S. Patent No. 5,165,407.
  • the entirety of the indicating electrode is covered by a membrane 42 of polyurethane, also as described in U.S. Patent No.
  • FIG. 4 is a schematic representation of a glucose collection and measurement system using this alternative glucose analysis method.
  • the sensor 30 described above with reference to Figure 3 is inserted into a glucose collection device attached to the patient's skin 18 as described with reference to Figures 1 and 2 above so that the sensor's aperture 44 is exposed to the glucose collection medium 12.
  • a conductor 60 leads from the indicating electrode of sensor 30 to a glucose measurement instrument 62.
  • a second conductor 64 leads from a reference electrode 66 attached to the patient's skin 18. Instrument 62 applies a voltage across conductors 60 and 64; the current measured across the electrodes is related to the concentration of glucose in the collection medium in a manner known in the art.
  • Glucose was collected from an adult human using an apparatus substantially similar to the apparatus shown in Figures 1 and 2.
  • the device was attached to the stratum corneum of the skin on the patient's forearm, and the device's reservoir was initially filled with a sample consisting of 0.5 ml. of distilled deionized water via a hypodermic needle and syringe.
  • the sample was withdrawn from the reservoir after five minutes and was replaced with a fresh sample of distilled deionized water at five minute intervals for a total of 30 minutes.
  • the final sample remained in the reservoir for 30 minutes before being withdrawn and analyzed.

Abstract

This invention is a noninvasive glucose monitoring apparatus and method that does not rely upon heat, electricity or chemicals to collect glucose from interstitial fluid across the patient's skin. Moreover, the method and apparatus monitor blood glucose in real time, i.e., in a time period short enough to enable a diabetic to take appropriate action to correct blood glucose levels. A collection device (10) comprising a reservoir (12) containing a glucose collection medium such as water is placed against the stratum corneum of the patient's skin for a predetermined period of time. At least a portion of the glucose collection medium is removed from the reservoir at the end of the predetermined time and analyzed for glucose concentration.

Description

NONINVASIVE GLUCOSE MONITOR
Background of the Invention
This invention relates generally to methods and apparatus for glucose collection and concentration measurement. In particular, the invention is directed to a method and apparatus for monitoring blood glucose levels noninvasively through a patient's skin.
People suffering from diabetes mellitus must monitor blood glucose levels over the course of the day. The most common prior art method of measuring blood glucose levels is by actually drawing a portion of the subject's blood and performing a chemical analysis on the sample. Continually drawing blood creates safety risks for the patient, however. The prior art has described "noninvasive" methods for measuring blood glucose levels. These supposedly noninvasive methods actually involve the application of chemicals, electricity, heat, or negative pressure to draw out body fluids other than blood that may nonetheless contain levels of glucose that correlate with blood glucose levels. For example, U.S. Patent No. 5,161,532 describes a glucose sensor that uses a pump to draw interstitial fluid out through the patient's skin into a sensor. The '532 patent states that any glucose in the interstitial fluid reacts with a chemical within the sensor to produce an electrical signal that is detected by a pair of electrodes.
U.S. Patent No. 5,036,861 describes a glucose monitor that collects the patient's sweat through a skin patch attached to the patient's wrist. Iontophoresis is used to transdermally introduce a gel into the patient's skin. The gel contains a cholinergic agent for stimulating the secretion mechanism of the eccrine sweat gland and agents that minimize or prevent loss of glucose from the sweat as it travels from the sweat gland to the skin patch. As in the '532 patent, the device described in the '861 patent measures the glucose level in the collected sweat using electrodes.
U.S. Patent No. 5,139,023 describes yet another "noninvasive" apparatus and method for monitoring blood glucose. The monitor includes a glucose receiving medium such as water enclosed in a housing that holds the receiving medium against the patient's epithelial membrane. The glucose receiving medium includes a permeation enhancing chemical such as a natural bile salt that enhances glucose permeability from interstitial fluid across the epithelial membrane into the monitor. An attempt to collect glucose according to the '023 method and apparatus but without any permeation enhancing agent failed to show that any glucose was collected.
Finally, published European Patent Application EP 0 304 304 discloses a transdermal glucose detection system in which the detector contains a porous carrier saturated with detector chemicals. The detector adhesively attaches to the patient's skin. A membrane serves as a barrier to prevent migration of the detector chemicals out of the detector while permitting glucose to migrate into the detector. Interaction between glucose and the detector chemicals causes a perceivable color change over a six to twelve hour period. The device only detects the presence of glucose; it does not measure the actual amount of glucose in the detector. Summary of the Invention
This invention provides a truly noninvasive glucose monitoring apparatus and method that does not rely upon heat, electricity or chemicals to collect glucose from interstitial fluid across the patient's skin. Moreover, the method and apparatus of this invention monitor blood glucose in real time, that is to say, in a time period short enough to enable a diabetic to take appropriate action to correct blood glucose levels.
In a preferred embodiment, a collection device comprising a reservoir containing a glucose collection medium such as water is placed against the stratum corneum of the patient's skin for a predetermined period of time. At least a portion of the glucose collection medium is removed from the reservoir at the end of the predetermined time and analyzed for glucose concentration.
Brief Description of the Drawings
Figure 1 is a side cross-sectional view of a glucose collection device according to the preferred embodiment of this invention.
Figure 2 is a bottom elevational view of the preferred glucose collection device.
Figure 3 is a cross-sectional view of a sensor for use with a glucose analysis method for use with this invention.
Figure 4 is a schematic representation of a glucose monitoring system according to this invention.
Detailed Description of the Preferred Embodiment
This invention presents a simple and noninvasive method for monitoring blood glucose levels. It is well-known that glucose can be found in a patient's interstitial fluid and in a patient's sweat. Heretofore, however, it had been thought that glucose could not cross the patient's skin in a detectable amount in real time without the use of a permeability enhancer. See, e.g., U.S. Patent No. 5,139,023 at col. 7, line 3. It had also been thought that even when sweat or interstitial fluid is actively extracted from the patient, active pharmacological agents are needed to preserve the presence of glucose in the extracted sample. See, e.g., U.S. Patent No. 5,036,861, col. 3, lines 1-10.
This invention is a method and apparatus for detecting blood glucose in a truly noninvasive manner without actively extracting interstitial fluid from the patient and without the use of sweat inducers, glucose preservers or permeability enhancers. In a preferred embodiment, glucose is collected through the stratum corneum of the patient's skin by a reservoir containing a glucose collection medium. After the passage of a predetermined time period, the glucose collection medium is analyzed to measure the quantity of glucose present. A preferred collection device for practicing this invention is shown in Figures 1 and 2. The device 10 comprises a reservoir 12 bordered by a cover 14, adhesive layer 16, and the stratum corneum of the patient's skin 18. As shown in part in Figure 2, the device is formed by attaching the plastic cover 14 to a double-sided adhesive 16 in which an oval or other-shaped hole has been formed. In the preferred embodiment, cover 14 is formed from cellophane plastic and adhesive layer 16 is Avery double-sided adhesive, part no. MED 3044.
The preferred glucose collection medium is distilled deionized water. According to the preferred method, the distilled deionized water is injected into reservoir 12 through a hypodermic needle and syringe 20. Despite suggestions to the contrary in the prior art, glucose will migrate from the patient's interstitial fluid through the skin 18 and into the water within reservoir 12. After the water has rested against the patient's skin for a predetermined period of time, the water is withdrawn for analysis. This glucose collection device and method can collect glucose from the patient without the use of chemicals or mechanical extraction.
Alternatively, a hydrogel may be used as a collection medium. Suitable hydrogels are described in U.S. Patent No. 5,139,023.
Water (or other collection medium) from the reservoir may be extracted at periodic intervals (preferably in the range of 5 to 10 minutes) and analyzed to determine its glucose content. A preferred glucose analysis method is described by LaCourse et al. in "Optimization of Waveforms for Pulsed Amperometric Detection of Carbohydrates Based on Pulsed Voltammetry, " 65 Analytical Chemistry 50-55 (1 January 1993) , although other analysis methods may be used. The preferred pulse amperometric voltammetry (PAD) analysis method combines high performance liquid chromatography with electrochemical detection using bi-directional voltage waveforms. Specifically, water extracted from the reservoir is diffused onto a chromatography column. The column is washed with a high pressure solvent such as a NaOH solution. A stepped voltage waveform is applied across two electrodes in the solution, one of which is a gold rotating disk electrode. The voltage waveform has three parts: a detection potential in the range of -200 to +400 mV for greater than 40 ms detection period, an oxidation potential in the range of 300 to 800 mV for greater than approximately 60 ms, and a reduction potential in the range of -800 to +100 mV for greater than approximately 60 ms. A plot of electrode current at the gold electrode versus applied voltage yields a curve with signature peaks at specific voltage values for certain solutes such as glucose. The peak amplitude or peak area are measures of the concentration of that solute. An alternative glucose concentration analysis method is shown schematically in Figures 3 and 4. The glucose measurement technique of this embodiment is similar to the enzymatic technique described in U.S. Patent No. 5,165,407 and does not require the glucose collection medium to be extracted from the collection device.
A glucose sensor 30 is shown in detail in Figure 3. A sensor body 32 is received within a stainless steel hollow tubular needle 34. The sensor body includes a Teflon-coated platinum-iridium wire 36
(90% Pt/10% Ir) having a total O.D. of about 0.2 mm and a cavity 38 formed therein. Cavity 38 is approximately 1.0 mm in length and is located about 3.0 mm from the distal tip of the wire 36. A glucose oxidase layer 40 is immobilized within the cavity 38, and comprises a cellulose acetate polymer layer attached to the surface of the Pt-Ir wire, with glucose oxidase crosslinked through glutaraldehyde onto the cellulose acetate to form an indicating electrode. The procedure is described in more detail in U.S. Patent No. 5,165,407. The entirety of the indicating electrode is covered by a membrane 42 of polyurethane, also as described in U.S. Patent No. 5,165,407, to control the diffusion rate of glucose onto the indicating electrode. Needle 34 has an aperture 44 adjacent its sharpened distal end 46 to expose layer 40. A silicone rubber plug 48 closes one end of the needle and a bead of epoxy 50 closes the other end, as shown. A plastic sheet 52 surrounding the proximal end of the needle serves as a holder. Figure 4 is a schematic representation of a glucose collection and measurement system using this alternative glucose analysis method. The sensor 30 described above with reference to Figure 3 is inserted into a glucose collection device attached to the patient's skin 18 as described with reference to Figures 1 and 2 above so that the sensor's aperture 44 is exposed to the glucose collection medium 12. A conductor 60 leads from the indicating electrode of sensor 30 to a glucose measurement instrument 62. A second conductor 64 leads from a reference electrode 66 attached to the patient's skin 18. Instrument 62 applies a voltage across conductors 60 and 64; the current measured across the electrodes is related to the concentration of glucose in the collection medium in a manner known in the art.
The invention may be further explained through the following examples. The examples are not intended as a limitation to any claimed embodiment.
Examples 1-5
Glucose was collected from an adult human using an apparatus substantially similar to the apparatus shown in Figures 1 and 2. The device was attached to the stratum corneum of the skin on the patient's forearm, and the device's reservoir was initially filled with a sample consisting of 0.5 ml. of distilled deionized water via a hypodermic needle and syringe. The sample was withdrawn from the reservoir after five minutes and was replaced with a fresh sample of distilled deionized water at five minute intervals for a total of 30 minutes. The final sample remained in the reservoir for 30 minutes before being withdrawn and analyzed.
The withdrawn samples were analyzed using pulsed amperometric voltammetry. The results are shown in Table I, with the glucose concentrations expressed in micromoles.
TABLE I
Sample 1 2 3 4 5
0-5 min 3.13μM 2.86 M 6.lOμM 9.24μM 1.66/iM
5-10 min 1.74 " 1.42 " 3.80 " 4.07 " 1.05 "
10-15 min 1.08 " 0.85 " 2.53 " 2.90 " 0.83 "
15-20 min 1.44 " 0.88 " 1.67 " 2.24 " 0.56 "
20-25 min 1.13 " 0.46 " 1.48 " 2.57 " 0.70 "
25-30 min 0.77 " 0.56 " 1.15 " 3.07 " 1.09 "
30-60 min 1.91 " 1.46 " 3.35 " 13.5 " 1.20 "

Claims

What is claimed is:
1. A noninvasive method of monitoring blood glucose across the skin of a patient without the use of a sweat inducer or a permeability enhancer, the method comprising the following steps: placing a reservoir of a glucose collection medium adjacent the patient's skin; and analyzing the glucose collection medium to measure the amount of glucose collected.
2. The method of claim 1 wherein the glucose collecting medium comprises water.
3. The method of claim l wherein the reservoir has an open side facing the patient's skin so that the glucose collection medium is in direct contact with the patient's skin.
4. The method of claim 1 wherein the reservoir comprises a glucose transfer membrane disposed between the glucose collection medium and the patient's skin.
5. The method of claim 1 wherein the . analyzing step comprises pulsed amperometric detection.
6. The method of claim 1 wherein the analyzing step is performed at the end of a predetermined time period in the range of 5 to 10 minutes.
7. The method of claim 6 wherein the glucose collecting medium consists essentially of water.
8. The method of claim 7 further comprising the step of removing the glucose collection medium from the reservoir before the analyzing step.
9. The method of claim 8 wherein the analyzing step comprises pulsed amperometric detection.
10. The method of claim 1 wherein the analyzing step comprises exposing an glucose-responsive enzyme to the glucose collection medium, the enzyme being in contact with an indicating electrode.
11. A noninvasive method of collecting glucose from a patient across the skin of a patient without the use of a sweat inducer or a permeability enhancer, the method comprising the steps of placing a reservoir of a glucose collection medium adjacent the patient's skin for a period of time and removing at least a portion of the glucose collection medium from the reservoir.
12. A noninvasive method of collecting glucose from a patient across the skin of a patient without the use of a sweat inducer or a permeability enhancer, the method comprising the steps of placing a reservoir of a glucose collection medium adjacent the patient's skin and exposing a glucose-responsive enzyme to the glucose collection medium, the glucose-responsive enzyme being in contact with an indicating electrode.
13. A glucose collection device comprising: a reservoir containing a glucose collection medium for collecting glucose from a patient in real time without the use of a permeability enhancer or a sweat inducer; and means for attaching the device to a patient so that glucose can travel across the patient's skin.
14. The device of claim 13 wherein the glucose collection medium comprises water.
15. The device of claim 13 wherein the means for attaching comprises adhesive.
16. The device of claim 13 further comprising means for extracting the glucose collection medium from the reservoir without detaching the device from the patient.
17. A glucose monitoring system comprising: a glucose collection device comprising a reservoir containing a glucose collection medium for collecting glucose from a patient in real time without the use of a permeability enhancer or a sweat inducer and means for attaching the device to a patient so that glucose can travel across the patient's skin; and means for measuring the concentration of glucose within the glucose collection medium.
18. The glucose monitoring system of claim 17 wherein the means for measuring comprises a glucose- responsive enzyme in contact with the glucose collection medium, an indicating electrode in contact with the enzyme, a reference electrode in contact with the patient's skin, and an instrument in electrical contact with the indicating electrode and the reference electrode.
PCT/US1994/006684 1993-07-16 1994-06-14 Noninvasive glucose monitor WO1995002357A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP7504544A JPH09503924A (en) 1993-07-16 1994-06-14 Non-invasive glucose monitor
EP94920190A EP0708615A4 (en) 1993-07-16 1994-06-14 Noninvasive glucose monitor
AU71073/94A AU7107394A (en) 1993-07-16 1994-06-14 Noninvasive glucose monitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9297593A 1993-07-16 1993-07-16
US08/092,975 1993-07-16

Publications (1)

Publication Number Publication Date
WO1995002357A1 true WO1995002357A1 (en) 1995-01-26

Family

ID=22236062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/006684 WO1995002357A1 (en) 1993-07-16 1994-06-14 Noninvasive glucose monitor

Country Status (5)

Country Link
EP (1) EP0708615A4 (en)
JP (1) JPH09503924A (en)
AU (1) AU7107394A (en)
CA (1) CA2167393A1 (en)
WO (1) WO1995002357A1 (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004190A3 (en) * 1996-07-30 1998-06-25 Dtr Dermal Therapy Inc Method and apparatus for non-invasive determination of glucose in body fluids
US5954685A (en) * 1996-05-24 1999-09-21 Cygnus, Inc. Electrochemical sensor with dual purpose electrode
US6144869A (en) * 1998-05-13 2000-11-07 Cygnus, Inc. Monitoring of physiological analytes
US6180416B1 (en) 1998-09-30 2001-01-30 Cygnus, Inc. Method and device for predicting physiological values
US6233471B1 (en) 1998-05-13 2001-05-15 Cygnus, Inc. Signal processing for measurement of physiological analysis
US6251083B1 (en) 1999-09-07 2001-06-26 Amira Medical Interstitial fluid methods and devices for determination of an analyte in the body
US6272364B1 (en) 1998-05-13 2001-08-07 Cygnus, Inc. Method and device for predicting physiological values
US6284126B1 (en) 1997-03-25 2001-09-04 Cygnus, Inc. Electrode with improved signal to noise ratio
US6326160B1 (en) 1998-09-30 2001-12-04 Cygnus, Inc. Microprocessors for use in a device for predicting physiological values
US6341232B1 (en) 1998-05-13 2002-01-22 Cygnus, Inc. Methods of producing collection assemblies, laminates, and autosensor assemblies for use in transdermal sampling systems
US6391643B1 (en) 1998-10-28 2002-05-21 Cygnus, Inc. Kit and method for quality control testing of an iontophoretic sampling system
US6561978B1 (en) 1999-02-12 2003-05-13 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
US6587705B1 (en) 1998-03-13 2003-07-01 Lynn Kim Biosensor, iontophoretic sampling system, and methods of use thereof
US6615078B1 (en) 1999-04-22 2003-09-02 Cygnus, Inc. Methods and devices for removing interfering species
US7150975B2 (en) 2002-08-19 2006-12-19 Animas Technologies, Llc Hydrogel composition for measuring glucose flux
US7497940B2 (en) 2003-09-02 2009-03-03 Koji Sode Glucose sensor and glucose level measuring apparatus
US7699775B2 (en) 2001-06-22 2010-04-20 Animas Technologies, Llc Methods for estimating analyte-related signals, microprocessors comprising programming to control performance of the methods, and analyte monitoring devices employing the methods
WO2010052849A1 (en) 2008-11-04 2010-05-14 パナソニック株式会社 Measurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program
EP2255724A1 (en) 2009-05-25 2010-12-01 Sysmex Corporation Method for analyzing analyte in tissue fluid, analyzer for analyzing analyte in tissue fluid, cartridge for analyzing analyte in tissue fluid, and kit for analyzing analyte in tissue fluid
EP2329771A3 (en) * 2004-07-13 2011-06-22 DexCom, Inc. Transcutaneous analyte sensor
US8690775B2 (en) 2004-07-13 2014-04-08 Dexcom, Inc. Transcutaneous analyte sensor
US8747316B2 (en) 2008-07-31 2014-06-10 Sysmex Corporation In vivo component measurement method, data processing method for in vivo component measurement, in vivo component measurement apparatus and collection member
US8870810B2 (en) 1998-12-18 2014-10-28 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US8886272B2 (en) 2004-07-13 2014-11-11 Dexcom, Inc. Analyte sensor
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
EP2998731A1 (en) * 2014-09-17 2016-03-23 i-Sens, Inc. Apparatus and method for measuring concentration of an analyte in whole blood samples
US9504413B2 (en) 2006-10-04 2016-11-29 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US9572527B2 (en) 2007-04-27 2017-02-21 Echo Therapeutics, Inc. Skin permeation device for analyte sensing or transdermal drug delivery
US9579053B2 (en) 2003-12-05 2017-02-28 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US9833143B2 (en) 2004-05-03 2017-12-05 Dexcom, Inc. Transcutaneous analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US10610137B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11432772B2 (en) 2006-08-02 2022-09-06 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US11559260B2 (en) 2003-08-22 2023-01-24 Dexcom, Inc. Systems and methods for processing analyte sensor data
US11589823B2 (en) 2003-08-22 2023-02-28 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8287483B2 (en) 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US20060094945A1 (en) 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5056521A (en) * 1989-06-29 1991-10-15 Health Craft International, Inc. Method for monitoring glucose level
US5076273A (en) * 1988-09-08 1991-12-31 Sudor Partners Method and apparatus for determination of chemical species in body fluid
US5139023A (en) * 1989-06-02 1992-08-18 Theratech Inc. Apparatus and method for noninvasive blood glucose monitoring

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK8601218A (en) * 1984-07-18 1986-03-17
US5050604A (en) * 1989-10-16 1991-09-24 Israel Reshef Apparatus and method for monitoring the health condition of a subject
US5140985A (en) * 1989-12-11 1992-08-25 Schroeder Jon M Noninvasive blood glucose measuring device
US5036861A (en) * 1990-01-11 1991-08-06 Sembrowich Walter L Method and apparatus for non-invasively monitoring plasma glucose levels

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5076273A (en) * 1988-09-08 1991-12-31 Sudor Partners Method and apparatus for determination of chemical species in body fluid
US5139023A (en) * 1989-06-02 1992-08-18 Theratech Inc. Apparatus and method for noninvasive blood glucose monitoring
US5056521A (en) * 1989-06-29 1991-10-15 Health Craft International, Inc. Method for monitoring glucose level

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0708615A4 *

Cited By (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5890489A (en) * 1996-04-23 1999-04-06 Dermal Therapy (Barbados) Inc. Method for non-invasive determination of glucose in body fluids
US5954685A (en) * 1996-05-24 1999-09-21 Cygnus, Inc. Electrochemical sensor with dual purpose electrode
WO1998004190A3 (en) * 1996-07-30 1998-06-25 Dtr Dermal Therapy Inc Method and apparatus for non-invasive determination of glucose in body fluids
USRE38681E1 (en) * 1997-03-25 2005-01-04 Cygnus, Inc. Electrode with improved signal to noise ratio
US6284126B1 (en) 1997-03-25 2001-09-04 Cygnus, Inc. Electrode with improved signal to noise ratio
US6587705B1 (en) 1998-03-13 2003-07-01 Lynn Kim Biosensor, iontophoretic sampling system, and methods of use thereof
US6999810B2 (en) 1998-03-13 2006-02-14 Animas Technologies Llc Biosensor and methods of use thereof
US6816742B2 (en) 1998-03-13 2004-11-09 Cygnus, Inc. Biosensor and methods of use thereof
US6736777B2 (en) 1998-03-13 2004-05-18 Cygnus, Inc. Biosensor, iontophoretic sampling system, and methods of use thereof
US6356776B1 (en) 1998-05-13 2002-03-12 Cygnus, Inc. Device for monitoring of physiological analytes
US6341232B1 (en) 1998-05-13 2002-01-22 Cygnus, Inc. Methods of producing collection assemblies, laminates, and autosensor assemblies for use in transdermal sampling systems
US6144869A (en) * 1998-05-13 2000-11-07 Cygnus, Inc. Monitoring of physiological analytes
US7295867B2 (en) 1998-05-13 2007-11-13 Animas Corporation Signal processing for measurement of physiological analytes
US6393318B1 (en) 1998-05-13 2002-05-21 Cygnus, Inc. Collection assemblies, laminates, and autosensor assemblies for use in transdermal sampling systems
US6438414B1 (en) 1998-05-13 2002-08-20 Cygnus, Inc. Collection assemblies, laminates, and autosensor assemblies for use in transdermal sampling systems
US6546269B1 (en) 1998-05-13 2003-04-08 Cygnus, Inc. Method and device for predicting physiological values
US7174199B2 (en) 1998-05-13 2007-02-06 Animas Technologies, Llc Monitoring a physiological analytes
US7873399B2 (en) 1998-05-13 2011-01-18 Animas Corporation Monitoring of physiological analytes
US6594514B2 (en) 1998-05-13 2003-07-15 Cygnus, Inc. Device for monitoring of physiological analytes
US6595919B2 (en) 1998-05-13 2003-07-22 Cygnus, Inc. Device for signal processing for measurement of physiological analytes
US6850790B2 (en) 1998-05-13 2005-02-01 Cygnus, Inc. Monitoring of physiological analytes
US6233471B1 (en) 1998-05-13 2001-05-15 Cygnus, Inc. Signal processing for measurement of physiological analysis
US6272364B1 (en) 1998-05-13 2001-08-07 Cygnus, Inc. Method and device for predicting physiological values
US6653091B1 (en) 1998-09-30 2003-11-25 Cyngnus, Inc. Method and device for predicting physiological values
US7935499B2 (en) 1998-09-30 2011-05-03 Animas Corporation Method and device for predicting physiological values
US6180416B1 (en) 1998-09-30 2001-01-30 Cygnus, Inc. Method and device for predicting physiological values
US6326160B1 (en) 1998-09-30 2001-12-04 Cygnus, Inc. Microprocessors for use in a device for predicting physiological values
US7405055B2 (en) 1998-09-30 2008-07-29 Animas Technologies Llc Method and device for predicting physiological values
US6391643B1 (en) 1998-10-28 2002-05-21 Cygnus, Inc. Kit and method for quality control testing of an iontophoretic sampling system
US8870810B2 (en) 1998-12-18 2014-10-28 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US7163511B2 (en) 1999-02-12 2007-01-16 Animas Technologies, Llc Devices and methods for frequent measurement of an analyte present in a biological system
US6561978B1 (en) 1999-02-12 2003-05-13 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
US7183068B2 (en) 1999-04-22 2007-02-27 Animas Technologies, Llc Methods of manufacturing glucose measuring assemblies with hydrogels
US6902905B2 (en) 1999-04-22 2005-06-07 Cygnus, Inc. Glucose measuring assembly with a hydrogel
US6615078B1 (en) 1999-04-22 2003-09-02 Cygnus, Inc. Methods and devices for removing interfering species
US6251083B1 (en) 1999-09-07 2001-06-26 Amira Medical Interstitial fluid methods and devices for determination of an analyte in the body
US7699775B2 (en) 2001-06-22 2010-04-20 Animas Technologies, Llc Methods for estimating analyte-related signals, microprocessors comprising programming to control performance of the methods, and analyte monitoring devices employing the methods
US7150975B2 (en) 2002-08-19 2006-12-19 Animas Technologies, Llc Hydrogel composition for measuring glucose flux
US11559260B2 (en) 2003-08-22 2023-01-24 Dexcom, Inc. Systems and methods for processing analyte sensor data
US11589823B2 (en) 2003-08-22 2023-02-28 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9585607B2 (en) 2003-08-22 2017-03-07 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9510782B2 (en) 2003-08-22 2016-12-06 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9420968B2 (en) 2003-08-22 2016-08-23 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8277636B2 (en) 2003-09-02 2012-10-02 Koji Sode Glucose sensor and glucose level measuring apparatus
US7497940B2 (en) 2003-09-02 2009-03-03 Koji Sode Glucose sensor and glucose level measuring apparatus
US9579053B2 (en) 2003-12-05 2017-02-28 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US10299712B2 (en) 2003-12-05 2019-05-28 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US10188333B2 (en) 2003-12-05 2019-01-29 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US9833143B2 (en) 2004-05-03 2017-12-05 Dexcom, Inc. Transcutaneous analyte sensor
US10327638B2 (en) 2004-05-03 2019-06-25 Dexcom, Inc. Transcutaneous analyte sensor
US10918315B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US8886272B2 (en) 2004-07-13 2014-11-11 Dexcom, Inc. Analyte sensor
US11883164B2 (en) 2004-07-13 2024-01-30 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8989833B2 (en) 2004-07-13 2015-03-24 Dexcom, Inc. Transcutaneous analyte sensor
US11064917B2 (en) 2004-07-13 2021-07-20 Dexcom, Inc. Analyte sensor
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US11045120B2 (en) 2004-07-13 2021-06-29 Dexcom, Inc. Analyte sensor
US11026605B1 (en) 2004-07-13 2021-06-08 Dexcom, Inc. Analyte sensor
US8690775B2 (en) 2004-07-13 2014-04-08 Dexcom, Inc. Transcutaneous analyte sensor
US10993641B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US10993642B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
EP2329771A3 (en) * 2004-07-13 2011-06-22 DexCom, Inc. Transcutaneous analyte sensor
US9603557B2 (en) 2004-07-13 2017-03-28 Dexcom, Inc. Transcutaneous analyte sensor
US9610031B2 (en) 2004-07-13 2017-04-04 Dexcom, Inc. Transcutaneous analyte sensor
US10980452B2 (en) 2004-07-13 2021-04-20 Dexcom, Inc. Analyte sensor
US10932700B2 (en) 2004-07-13 2021-03-02 Dexcom, Inc. Analyte sensor
US9801572B2 (en) 2004-07-13 2017-10-31 Dexcom, Inc. Transcutaneous analyte sensor
US9814414B2 (en) 2004-07-13 2017-11-14 Dexcom, Inc. Transcutaneous analyte sensor
US9833176B2 (en) 2004-07-13 2017-12-05 Dexcom, Inc. Transcutaneous analyte sensor
US8858434B2 (en) 2004-07-13 2014-10-14 Dexcom, Inc. Transcutaneous analyte sensor
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US10918314B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US10022078B2 (en) 2004-07-13 2018-07-17 Dexcom, Inc. Analyte sensor
US10918313B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10709362B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US9078626B2 (en) 2004-07-13 2015-07-14 Dexcom, Inc. Transcutaneous analyte sensor
US10827956B2 (en) 2004-07-13 2020-11-10 Dexcom, Inc. Analyte sensor
US9060742B2 (en) 2004-07-13 2015-06-23 Dexcom, Inc. Transcutaneous analyte sensor
US10314525B2 (en) 2004-07-13 2019-06-11 Dexcom, Inc. Analyte sensor
US9044199B2 (en) 2004-07-13 2015-06-02 Dexcom, Inc. Transcutaneous analyte sensor
US10524703B2 (en) 2004-07-13 2020-01-07 Dexcom, Inc. Transcutaneous analyte sensor
US10813576B2 (en) 2004-07-13 2020-10-27 Dexcom, Inc. Analyte sensor
US10799158B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US10799159B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US10722152B2 (en) 2004-07-13 2020-07-28 Dexcom, Inc. Analyte sensor
US9668677B2 (en) 2004-07-13 2017-06-06 Dexcom, Inc. Analyte sensor
US10709363B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10918317B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11051726B2 (en) 2005-03-10 2021-07-06 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10709364B2 (en) 2005-03-10 2020-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10716498B2 (en) 2005-03-10 2020-07-21 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10617336B2 (en) 2005-03-10 2020-04-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10743801B2 (en) 2005-03-10 2020-08-18 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610135B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10925524B2 (en) 2005-03-10 2021-02-23 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610137B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10856787B2 (en) 2005-03-10 2020-12-08 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11000213B2 (en) 2005-03-10 2021-05-11 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610136B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10898114B2 (en) 2005-03-10 2021-01-26 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918318B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918316B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor
US11432772B2 (en) 2006-08-02 2022-09-06 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US10136844B2 (en) 2006-10-04 2018-11-27 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11399745B2 (en) 2006-10-04 2022-08-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US9504413B2 (en) 2006-10-04 2016-11-29 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US9572527B2 (en) 2007-04-27 2017-02-21 Echo Therapeutics, Inc. Skin permeation device for analyte sensing or transdermal drug delivery
US8747316B2 (en) 2008-07-31 2014-06-10 Sysmex Corporation In vivo component measurement method, data processing method for in vivo component measurement, in vivo component measurement apparatus and collection member
US11751815B2 (en) 2008-11-04 2023-09-12 Phc Holdings Corporation Measurement device
US8597570B2 (en) 2008-11-04 2013-12-03 Panasonic Corporation Measurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program
EP3315958A1 (en) 2008-11-04 2018-05-02 Panasonic Healthcare Holdings Co., Ltd. Measurement device
US9855011B2 (en) 2008-11-04 2018-01-02 Panasonic Healthcare Holdings Co., Ltd. Measurement device
US10070822B2 (en) 2008-11-04 2018-09-11 Phc Holdings Corporation Measurement Device
WO2010052849A1 (en) 2008-11-04 2010-05-14 パナソニック株式会社 Measurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program
US9622690B2 (en) 2008-11-04 2017-04-18 Panasonic Healthcare Holdings Co., Ltd. Measurement device
US10687762B2 (en) 2008-11-04 2020-06-23 Phc Holdings Corporation Measurement device
EP3043174A1 (en) 2008-11-04 2016-07-13 Panasonic Healthcare Holdings Co., Ltd. Measurement device
EP2255724A1 (en) 2009-05-25 2010-12-01 Sysmex Corporation Method for analyzing analyte in tissue fluid, analyzer for analyzing analyte in tissue fluid, cartridge for analyzing analyte in tissue fluid, and kit for analyzing analyte in tissue fluid
US11378540B2 (en) 2014-09-17 2022-07-05 I-Sens, Inc. Apparatus and method for measuring concentration of an analyte in bio-samples
CN105738430B (en) * 2014-09-17 2019-02-22 爱-森新株式会社 The concentration detection method and detection device of substance to be analyzed in biological sample
CN105738430A (en) * 2014-09-17 2016-07-06 爱-森新株式会社 Apparatus and method for measuring concentration of an analyte in whole blood samples
US10690619B2 (en) 2014-09-17 2020-06-23 I-Sens, Inc. Apparatus and method for measuring concentration of an analyte in whole blood samples
EP2998731A1 (en) * 2014-09-17 2016-03-23 i-Sens, Inc. Apparatus and method for measuring concentration of an analyte in whole blood samples

Also Published As

Publication number Publication date
CA2167393A1 (en) 1995-01-26
EP0708615A4 (en) 1996-10-16
EP0708615A1 (en) 1996-05-01
AU7107394A (en) 1995-02-13
JPH09503924A (en) 1997-04-22

Similar Documents

Publication Publication Date Title
WO1995002357A1 (en) Noninvasive glucose monitor
US8046043B2 (en) Extraction device, analyzer, extraction method, and analysis method
CA2332112C (en) Monitoring of physiological analytes
US7066884B2 (en) System, method, and device for non-invasive body fluid sampling and analysis
US8224414B2 (en) System and method for analyte sampling and analysis with hydrogel
AU2944995A (en) Iontophoretic sampling device and method
US20070027383A1 (en) Patches, systems, and methods for non-invasive glucose measurement
EP1776035A2 (en) Non-invasive glucose measurement
ATE75128T1 (en) IMPLANTABLE ELECTROCHEMICAL SENSOR.
WO2006050033A9 (en) System and method for analyte sampling and analysis
EP1225831A2 (en) Non-invasive body fluid sampling and analysis
JP2005218855A (en) Percutaneous analyte extraction kit, percutaneous analyte extraction apparatus, blood sugar level measuring apparatus, percutaneous analyte extraction method, and blood sugar level measuring method
KR20010109506A (en) Extracting System for Glucose in Skin Layer Using Electroosmosis Effect
KR20010067623A (en) Noninvasive Glucose Extraction through Skin by Reverse Iontophoresis or Electroosmosis
KR20190014875A (en) Invasive continuous glucose monitoring system applying reverse iontophoresis and continuous glucose monitoring method using thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP KR NO NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994920190

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2167393

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994920190

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994920190

Country of ref document: EP